Pluristem therapeutics inc (PSTI)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Revenues

-

0

-

54

54

54

54

50

0

0

0

-

0

0

-

2,847

2,941

3,036

379

379

379

379

379

379

380

479

579

679

915

951

757

716

384

154

0

-

0

0

-

Cost of revenues

-

0

-

-

-

0

-

2

0

0

0

-

0

0

-

100

103

106

13

13

12

12

11

11

11

14

17

20

27

27

22

21

0

0

0

-

-

-

-

Gross profit

-

0

-

52

52

52

52

48

0

0

0

-

0

0

-

2,747

2,838

2,930

366

366

367

367

368

368

369

465

562

659

887

923

735

695

0

0

0

-

-

-

-

Research and development expenses

23,404

26,083

27,943

29,882

31,057

30,117

28,944

26,371

24,842

23,940

23,162

24,001

24,520

23,738

23,828

22,856

22,540

22,925

22,739

23,416

23,752

24,455

25,177

24,938

25,536

23,616

21,655

19,906

19,257

17,713

13,570

12,685

8,765

7,489

9,673

8,311

0

0

0

Less: participation by the Israeli Innovation Authority (IIA), Horizon 2020 and other parties

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Less: participation by the Israeli Innovation Authority (IIA), Horizon 2020 and other parties

-

2,654

2,898

-

-

4,783

4,228

3,742

3,590

2,733

2,391

2,909

3,624

3,423

3,378

3,276

3,156

3,203

3,475

4,243

4,278

4,227

4,721

5,396

3,414

0

0

-

0

-

-

-

-

-

-

-

-

-

-

Less participation by the Office of the Chief Scientist and other parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

558

-550

-1,160

-1,682

0

0

0

Research and development expenses, net

21,319

23,429

25,045

26,427

26,779

25,334

24,716

22,629

21,252

21,207

20,771

21,092

20,896

20,315

20,450

19,580

19,384

19,722

19,264

19,173

19,474

20,228

20,456

19,542

20,998

19,112

17,658

17,233

14,715

12,663

9,012

9,158

8,261

6,898

8,475

6,629

0

0

0

General and administrative expenses, net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative expenses, net

-

8,387

8,760

-

-

9,843

10,640

11,193

10,380

9,600

8,126

6,927

6,710

6,463

6,563

6,486

6,414

6,302

6,269

6,460

7,059

8,063

8,525

8,676

7,724

6,352

5,797

5,649

7,265

8,030

6,612

6,568

4,893

4,121

5,366

4,485

0

0

0

Other income

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Operating loss

-28,893

-31,794

-33,757

-35,532

-36,377

-35,125

-35,261

-33,731

-31,541

-30,716

-28,897

-28,019

-27,606

-26,778

-24,358

-23,319

-22,960

-23,094

-25,167

-25,267

-26,166

-27,924

-28,613

-27,850

-28,353

-24,999

-22,893

-22,223

-21,093

-19,770

-14,889

-15,031

-12,781

-10,870

-13,692

-11,114

0

0

0

Financial income (expense), net

117

447

97

225

-151

7,144

7,734

7,605

7,380

222

22

205

603

436

664

73

624

735

525

590

588

296

525

918

654

1,037

0

-

0

0

-

-

-

-

-

-

-

-

-

Financial income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

387

37

40

266

0

0

0

Net loss for the period

-28,776

-31,347

-33,660

-35,307

-36,528

-27,981

-27,527

-26,126

-24,161

-30,494

-28,875

-27,814

-27,003

-26,342

-23,694

-23,246

-22,336

-22,359

-24,642

-24,677

-25,578

-27,628

-28,088

-26,932

-27,726

-24,130

-21,915

-21,155

-20,290

-18,784

-14,296

-14,794

-12,393

-10,832

-13,652

-10,848

0

0

0

Basic and diluted net loss per share (in Dollars per share)

-0.42

-0.40

-0.46

-0.52

-0.86

-0.75

-0.77

-2.33

-0.01

-0.08

-0.08

-2.95

-0.09

-0.08

-0.08

-0.08

-0.09

-0.05

-0.07

-0.07

-0.10

-0.09

-0.09

-0.09

-0.14

-0.11

-0.08

-0.12

-0.10

-0.08

-0.08

-0.09

-0.09

-0.05

-0.11

-0.09

-0.07

-0.11

-0.08

Weighted average number of shares used in computing basic and diluted net loss per share (in Shares)

17,823

15,927

15,405

14,664

11,722

11,579

11,365

-270,145

110,044

105,130

97,321

-218,497

91,753

81,038

80,674

80,181

79,935

79,370

78,704

71,267

70,668

70,070

69,131

67,684

65,607

61,510

59,254

58,220

58,358

57,512

47,833

-

44,328

43,669

-

-

-

-

-

Weighted average number of shares used in computing basic and diluted net loss per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

42,779

42,209

36,676

24,897

21,012